Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics
MIST Price/Volume Stats
| Current price | $1.45 | 52-week high | $3.52 |
| Prev. close | $1.48 | 52-week low | $1.12 |
| Day low | $1.43 | Volume | 101,284 |
| Day high | $1.49 | Avg. volume | 218,065 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $1.71 | Market Cap | 77.23M |
MIST Stock Price Chart Interactive Chart >
Milestone Pharmaceuticals Inc. (MIST) Company Bio
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Latest MIST News From Around the Web
Below are the latest news stories about MILESTONE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIST as an investment opportunity.
Milestone Pharma (MIST) Down on Regulatory Update for EtripamilMilestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT. |
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVTMONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Upon preliminary review, the FDA determined that the NDA, submitted in October 2023, was not sufficiently complete to p |
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) top owners are individual investors with 52% stake, while 34% is held by institutionsKey Insights Significant control over Milestone Pharmaceuticals by individual investors implies that the general public... |
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceMilestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time. |
Milestone Pharmaceuticals Third Quarter 2023 Earnings: US$0.45 loss per share (vs US$0.34 loss in 3Q 2022)Milestone Pharmaceuticals ( NASDAQ:MIST ) Third Quarter 2023 Results Key Financial Results Net loss: US$15.1m (loss... |
MIST Price Returns
| 1-mo | 2.84% |
| 3-mo | 1.40% |
| 6-mo | 0.00% |
| 1-year | -53.07% |
| 3-year | -74.65% |
| 5-year | -93.49% |
| YTD | -13.17% |
| 2023 | -57.83% |
| 2022 | -39.54% |
| 2021 | -2.24% |
| 2020 | -58.15% |
| 2019 | N/A |
Loading social stream, please wait...